Janice M. Walshe

St. Vincent's University Hospital — Ireland

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index5.5kcitations153works8.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(48), Advanced Breast Cancer Therapies(46), HER2/EGFR in Cancer Research(44), Cancer Treatment and Pharmacology(40), Cancer Risks and Factors(22)

Publications152 total

Achieving Pregnancy After Early Hormone Receptor-Positive Breast Cancer: Recent Evidence and Clinical Considerations
Cancers·2026Open Access
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients
Oncogene·2025Open Access
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy
Clinical Cancer Research·2025
Corrigendum to “Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]
The Breast·2025Open Access
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial
The Breast·2025Open Access
Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial
Journal of Clinical Oncology·2025· 3 citedOpen Access
Abstract P5-05-21: Tumor/stromal infiltration of Natural Killer (NK) cells and overall survival (OS) in patients (pts) with metastatic (met) HER2+ breast cancer (BC)
Clinical Cancer Research·2025
Abstract P2-12-12: Impact of the addition of pembrolizumab to neoadjuvant chemotherapy in triple negative breast cancer in Ireland: a retrospective, multi-centre, real-world study
Clinical Cancer Research·2025
TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, rastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis
Acta Oncologica·2025· 1 citedOpen Access
CTRIAL-IE (ICORG) 15–34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland
Irish Journal of Medical Science (1971 -)·2025Open Access
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
Journal of Clinical Oncology·2024· 18 cited
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial
Journal of Clinical Oncology·2024· 9 citedOpen Access
Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy
Journal of Clinical Oncology·2024· 25 citedOpen Access
Abstract GS02-11: Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
Cancer Research·2024· 1 cited
Abstract PO5-02-04: Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)
Cancer Research·2024
Supplementary Figure S1 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
2024Open Access
Supplementary Table from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
2024Open Access
Data from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
2024Open Access
Supplementary Figure S1 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
2024Open Access
Supplementary Figure S2 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Sandra M. Swain(15), Catherine M. Kelly(9), Richard S. Finn(7), Hope S. Rugo(7), Karen A. Gelmon(7), Dongrui R. Lu(7), Véronique Dièras(7), Neelima Denduluri(7), Martine Piccart(7), Eleftherios P. Mamounas(7), Hanna Bandos(7), Charles E. Geyer(7), Priya Rastogi(7), Louis Fehrenbacher(7), Stephen Chia(7), Adam Brufsky(7), Gamini S. Soori(7), Shaker R. Dakhil(7), Norman Wolmark(7), John Crown(7)